Novel Biomarkers for Early Detection of Acute Kidney Injury: A Mini Review

Sergio Cundari^*
*Correspondence: Sergio Cundari, Department of Nephropathology, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, 91054 Erlangen, Germany, Email:

Keywords

Acute kidney injury • Biomarkers • Early detection • NGAL

Introduction

Acute Kidney Injury (AKI) represents a significant clinical challenge due to its rapid onset and the potential for severe outcomes, including chronic kidney disease and increased mortality. Traditionally, AKI has been diagnosed using serum creatinine levels and urine output, which are late markers of kidney dysfunction and do not accurately reflect early kidney damage. The delay in diagnosis often limits the effectiveness of therapeutic interventions, underscoring the need for more sensitive and specific biomarkers that can detect kidney injury at an earlier stage. Recent research has focused on identifying novel biomarkers that could improve the early detection and risk stratification of AKI, offering the potential to enhance patient management and outcomes [1].

Literature Review

Recent advancements in biomarker research have significantly expanded our understanding of Acute Kidney Injury (AKI) and its early detection. Traditional diagnostic methods, relying heavily on serum creatinine levels and urine output, have been found insufficient for timely diagnosis due to their delayed response to kidney injury. This has led to a growing interest in novel biomarkers that can detect AKI earlier, providing a critical window for intervention. One of the most promising biomarkers identified is Neutrophil Gelatinase-Associated Lipocalin. NGAL is a small protein that is released from renal tubular cells in response to injury. It is rapidly detectable in both blood and urine, often within a few hours of kidney insult, which is much earlier than the rise in serum creatinine. This early response makes NGAL a valuable biomarker for predicting AKI, particularly in settings like cardiac surgery or nephrotoxic drug exposure, where timely intervention can significantly alter the course of the disease. Moreover, studies have shown that NGAL levels correlate with the severity of kidney injury, making it a useful tool not only for early detection but also for assessing the extent of damage [2]. Another key biomarker is Kidney Injury Molecule-1 (KIM-1), a type 1 transmembrane protein that is minimally expressed in healthy kidneys but is significantly upregulated in proximal tubular cells following injury. KIM-1 is released into the urine, where it can be detected in the early stages of AKI. Its specificity to tubular injury makes it a particularly valuable marker for distinguishing AKI from other forms of kidney dysfunction. KIM-1's ability to detect subclinical injury, even before significant changes in serum creatinine occur, positions it as a critical biomarker for early diagnosis and intervention. Interleukin-18 (IL-18) is another biomarker that has gained attention for its role in the early detection of AKI. IL-18 is a pro-inflammatory cytokine produced in response to ischemic and toxic renal injuries. Elevated levels of IL-18 in urine have been observed in patients at risk for AKI, particularly in those with sepsis or undergoing cardiac surgery. IL-18 not only serves as an early marker of injury but also provides insights into the inflammatory processes that underlie AKI, which could guide targeted therapeutic strategies [3].

Beyond these three primary biomarkers, other novel candidates such as Cystatin C, Liver-Type Fatty Acid-Binding Protein (L-FABP), and Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) in combination with Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) are being investigated for their potential roles in early AKI detection. Cystatin C, for example, is a marker of glomerular filtration that rises earlier than creatinine in AKI, while L-FABP reflects tubular damage and oxidative stress. TIMP-2 and IGFBP7, which are involved in cell cycle arrest, have been proposed as markers for identifying patients at high risk for developing AKI [4].

Collectively, these biomarkers represent a significant advancement in the early detection of AKI. They offer the potential to diagnose AKI at a stage where interventions can be most effective, reducing the risk of progression to more severe kidney injury or chronic kidney disease. However, despite their promise, the clinical application of these biomarkers requires further validation. Large-scale studies are needed to confirm their accuracy, reliability, and utility across different patient populations and clinical settings. Additionally, the development of standardized protocols for biomarker measurement and interpretation will be crucial for their integration into routine clinical practice [5].

Discussion

The identification of novel biomarkers for AKI has the potential to significantly change the landscape of kidney injury diagnosis and management. NGAL, KIM-1, and IL-18 are among the most promising biomarkers, offering greater sensitivity and specificity for early detection compared to traditional markers like serum creatinine. The early detection of AKI using these biomarkers could facilitate timely interventions, potentially reducing the incidence of severe kidney injury and improving patient outcomes. However, there are challenges to the widespread adoption of these biomarkers. Variability in biomarker levels due to different causes of AKI, patient populations, and underlying conditions can complicate their interpretation. Additionally, the cost and availability of biomarker assays, along with the need for standardized thresholds and protocols, are significant barriers that need to be addressed. Further research is needed to establish the clinical utility of these biomarkers across diverse populations and settings, as well as to integrate them into existing diagnostic frameworks [6].

Conclusion

Novel biomarkers such as NGAL, KIM-1, and IL-18 represent a promising advance in the early detection of Acute Kidney Injury, offering the potential to improve diagnosis and patient outcomes. While these biomarkers have shown significant potential in research settings, their clinical implementation requires further validation and standardization. The integration of these biomarkers into routine clinical practice could revolutionize AKI management by enabling earlier diagnosis and more effective therapeutic interventions, ultimately reducing the burden of this serious condition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Vaheri, Antti, Tomas Strandin, Jussi Hepojoki and Tarja Sironen, et al. "Uncovering the mysteries of hantavirus infections." Nat Rev Microbiol 11 (2013): 539-550.

   Google Scholar, Crossref, Indexed at

2. Ferluga, Dušan and Alenka Vizjak. "Hantavirus nephropathy." J Am Soc Nephrol 19 (2008): 1653-1658.

   Google Scholar, Crossref, Indexed at

3. Boehlke, Christopher, Björn Hartleben, Tobias B. Huber and Helmut Hopfer, et al. "Hantavirus infection with severe proteinuria and podocyte foot-process effacement." Am J Kidney Dis 64 (2014): 452-456.

   Google Scholar, Crossref, Indexed at

4. Nusshag, Christian, Alisa Stütz, Stefan Hägele and Claudius Speer, et al. "Glomerular filtration barrier dysfunction in a self-limiting, RNA virus-induced glomerulopathy resembles findings in idiopathic nephrotic syndromes." Sci Rep 10 (2020): 19117.

   Google Scholar, Crossref, Indexed at

5. Nusshag, Christian, Lukas Boegelein, Pamela Schreiber and Sandra Essbauer, et al. "Expression profile of human renal mesangial cells is altered by infection with pathogenic Puumala orthohantavirus." Viruses 14 (2022): 823.

   Google Scholar, Crossref, Indexed at

6. Outinen, Tuula K., Satu Mäkelä, Ilkka Pörsti and Antti Vaheri, et al. "Severity biomarkers in Puumala hantavirus infection." Viruses 14 (2021): 45.

   Google Scholar, Crossref, Indexed at